Insmed Inc (INSM)vsXenon Pharmaceuticals Inc (XENE)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
XENE
Xenon Pharmaceuticals Inc
$55.57
+4.10%
HEALTHCARE · Cap: $5.09B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 7986% more annual revenue ($606.42M vs $7.50M). XENE leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
XENE
Avoid22
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -51.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : XENE
The strongest argument for XENE centers on Altman Z-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : XENE
The primary concerns for XENE are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while XENE is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
XENE generates stronger free cash flow (-82M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Xenon Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company is headquartered in Burnaby, Canada.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?